Affiliations 

  • 1 Fu Wai Hospital Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
  • 2 National Taiwan University Hospital, Taipei, Taiwan
  • 3 Madras Medical Mission, Chennai, India
  • 4 King Fahad Armed Forces Hospital, Jeddah, Saudi Arabia
  • 5 Clinical Research Centre, Queen Elizabeth Hospital II, Sabah, Malaysia
  • 6 Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea
  • 7 National Heart Foundation Hospital and Research Institute, Dhaka, Bangladesh
  • 8 The Military Hospital of Tunis, Tunis, Tunisia
  • 9 Sarawak Heart Centre, Sarawak, Malaysia
  • 10 Kaohsiung Chang Gung Memorial Hospital of CGMF, Kaohsiung, Taiwan
  • 11 West China Hospital, Sichuan University, Chengdu, China
  • 12 Fortis Escorts Heart Institute, New Delhi, India
  • 13 Sejong General Hospital, Bucheon-si, South Korea
  • 14 National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan
  • 15 Chang Gung Memorial Hospital Linkou and Chang Gung University, Taoyuan City, Taiwan
  • 16 Medtronic Korea, Seoul, South Korea
  • 17 Medtronic Australasia, Sydney, Australia
  • 18 Medtronic Inc, Mounds View, Minnesota, USA
JACC Asia, 2022 Oct;2(5):559-571.
PMID: 36518723 DOI: 10.1016/j.jacasi.2022.06.006

Abstract

BACKGROUND: Implantable cardioverter-defibrillator (ICD) implantation to prevent sudden cardiac death (SCD) in post-myocardial infarction (MI) patients varies by geography but remains low in many regions despite guideline recommendations.

OBJECTIVES: This study aimed to characterize the care pathway of post-MI patients and understand barriers to referral for further SCD risk stratification and management in patients meeting referral criteria.

METHODS: This prospective, nonrandomized, multi-nation study included patients ≥18 years of age, with an acute MI ≤30 days and left ventricular ejection fraction <50% ≤14 days post-MI. The primary endpoint was defined as the physician's decision to refer a patient for SCD stratification and management.

RESULTS: In total, 1,491 post-MI patients were enrolled (60.2 ± 12.0 years of age, 82.4% male). During the study, 26.7% (n = 398) of patients met criteria for further SCD risk stratification; however, only 59.3% of those meeting criteria (n = 236; 95% CI: 54.4%-64.0%) were referred for a visit. Of patients referred for SCD risk stratification and management, 94.9% (n = 224) attended the visit of which 56.7% (n =127; 95% CI: 50.1%-63.0%) met ICD indication criteria. Of patients who met ICD indication criteria, 14.2% (n = 18) were implanted.

CONCLUSIONS: We found that ∼40% of patients meeting criteria were not referred for further SCD risk stratification and management and ∼85% of patients who met ICD indications did not receive a guideline-directed ICD. Physician and patient reasons for refusing referral to SCD risk stratification and management or ICD implant varied by geography suggesting that improvement will require both physician- and patient-focused approaches. (Improve Sudden Cardiac Arrest [SCA] Bridge Study; NCT03715790).

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.